Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 9/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 11/20 | 0.41 |
| ▸ | HTR2B | P41595 | 8/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6327503 | 0.82 | HTR2C (0.42) | HTR2AHTR2CHTR2B | |
| SCHEMBL6326980 | 0.80 | ITGB3 (0.43) | ITGB3ITGAVITGB6HTR2AHTR2C | |
| SCHEMBL15669519 | 0.77 | KDM1A (0.57) | ITGB3ITGAVITGB6HTR2AFFAR1 | |
| SCHEMBL2432912 | 0.77 | FFAR1 (0.53) | HTR2AFFAR1HTR2CHTR2B | |
| SCHEMBL27404166 | 0.77 | HTR2C (0.60) | ITGB3ITGAVITGB6HTR2AHTR2C | |
| SCHEMBL6319047 | 0.74 | CA1 (0.48) | ITGB3ITGAVITGB6CA1CA2 | |
| SCHEMBL6319144 | 0.74 | KDM1A (0.36) | HTR2AFFAR1HTR2CHTR2BMRGPRX4 | |
| SCHEMBL28037017 | 0.72 | KDM1A (0.56) | HTR2AHTR2CHTR2B | |
| SCHEMBL15669104 | 0.71 | KDM1A (0.50) | ITGB3ITGAVITGB6HTR2AFFAR1 | |
| SCHEMBL6321347 | 0.70 | EPHX2 (0.39) | HTR2AFFAR1HTR2CHTR2BMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | ITGB3 4458/4885ITGAV 4392/4885ITGB6 4730/4885 |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 6/4885ITGB6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.